Showing 1351-1360 of 1555 results for "".
- PharmAbcine Announces Nonclinical Data of PMC-403 for Vessel-Related Diseases at ARVOhttps://modernod.com/news/pharmabcine-announces-nonclinical-data-of-pmc-403-for-vessel-related-diseases-at-arvo/2479187/PharmAbcine announced that the company presented an e-poster featuring nonclinical data of PMC-403 at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting on May 5th. PMC-403 is the company’s novel agonistic ant
- Ceyeber Announces Advisory Board of World-Renowned Ophthalmologistshttps://modernod.com/news/ceyeber-announces-advisory-board-of-world-renowned-ophthalmologists/2479167/Ceyeber, the developer of implantable intraocular lens technology designed for medical applications and augmented reality, has created a Medical Advisory Board consisting of top ophthalmologists. Ceyeber’s founder and CEO, Robert E. Grant, said, “
- Allegro Ophthalmics Announces New Scientific Data to Be Presented During the 2021 ARVO Annual Meetinghttps://modernod.com/news/allegro-ophthalmics-announces-new-scientific-data-to-be-presented-during-the-2021-arvo-annual-meeting/2479123/Allegro Ophthalmics announced that four scientific posters involving risuteganib, the company’s lead investigational compound in retina, will be presented during the 2021 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, being held virtually May 1-7, 2021. “It’s e
- Biden Aims to Release All Available COVID-19 Vaccine Doses to Speed Up Distribution: Reporthttps://modernod.com/news/biden-aims-to-release-all-available-covid-19-vaccine-doses-to-speed-up-distribution-report/2478739/President-elect Joe Biden will seek to release nearly every available dose of the coronavirus vaccine when he takes office later this month, a move that signals a departure from the Trump administration and the FDA’s current stance of holding back half of the US vaccine supply in order to e
- WHO Validates Pfizer, BioNTech’s COVID-19 Vaccine for Emergency Usehttps://modernod.com/news/who-validates-pfizer-biontechs-covid-19-vaccine-for-emergency-use/2478709/The World Health Organization (WHO) said Pfizer and BioNTech’s COVID-19 vaccine BNT162b2 became the first vaccine to receive WHO validation for emergency use since the pandemic began. According to the WHO, BNT162b2 has met the agency’s “must-have” criteria for safety and e
- Innovent Announces the Results of the Phase 1 Clinical Trial of IBI302 for Wet AMD at AAO 2020https://modernod.com/news/innovent-announces-the-results-of-the-phase-1-clinical-trial-of-ibi302-for-wet-amd-at-aao-2020/2478560/Innovent Biologics announces that the results of the phase 1 clinical trial of IBI302, a first-in-class ophthalmic recombinant human anti-VEGF and anti-complement bi-specific fusion protein for wet age-related macular degeneration (AMD) is released in e-poster at 2020 American Academy of Ophthalm
- I-MED Pharma Launches Tearcheck Dry Eye Analysis in Canadahttps://modernod.com/news/i-med-pharma-launches-tearcheck-dry-eye-analysis-in-canada/2478522/I-MED Pharma announced the Canadian launch of tearcheck, a diagnostic and analyzing tool that performs 9 exams in under 10 minutes. The tearcheck was designed and developed by the French manufacturer E-Swin and offers the newest technological advancements to simplify dry eye d
- Staar Surgical Announces Completion of Patient Enrollment in EVO Implantable Lens US Clinical Trialhttps://modernod.com/news/staar-surgical-announces-completion-of-patient-enrollment-in-evo-implantable-lens-us-clinical-trial/2478275/Staar Surgical has announced that patient enrollment for the primary study analysis cohort of 300 subjects has been achieved in its FDA clinical trial, “A Multicenter Clinical Evaluation of the EVO/EVO+ Visian Implantable Collamer Lens.” Primary study analysis will be conducted when 300 primary e
- Pharma Company Exercises Rights for Exclusive Use of Everads Drug Delivery Technology in Specific Retinal Targetshttps://modernod.com/news/pharma-company-exercises-rights-for-exclusive-use-of-everads-drug-delivery-technology-in-specific-retinal-targets/2478193/Everads Therapy has granted a pharmaceutical company a time-limited exclusivity for utilizing Everads’ suprachoroidal delivery technology for the development of specific ocular targets. In exchange for exclusivity of these specific ocular targets, Everads will receive a milestone payment. E
- CooperVision Acquires GP Specialists, Expanding Specialty EyeCare Business and Ortho-K Optionshttps://modernod.com/news/coopervision-acquires-gp-specialists-expanding-specialty-eyecare-business-and-ortho-k-options/2478137/CooperVision has acquired C&E GP Specialists, a customized orthokeratology contact lens manufacturer and distributor. The move expands CooperVision’s Specialty eye care business. Terms of the deal were not disclosed. “CooperVision is committed to providing eye care professionals